About GERD Drugs
Gastroesophageal reflux disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the stomach and esophagus. It occurs when acidic stomach juices, or food and fluids flow back up into the food pipe (esophagus). The backwash irritates the lining of the esophagus and causes GERD. It affects all ages from infants to older adults. The symptoms of GERD include difficulty while swallowing (dysphagia), heartburn sensation, regurgitation or acid reflux, dry cough, sore throat, and chest pain.
GERD is believed to be caused by the overuse of certain medications, such as calcium channel blockers, nitrates and antihistamines. Unhealthy lifestyle factors such as smoking, drinking, slouching, consuming caffeinated drinks, eating large meals, and sleeping immediately after eating are some other typical causes for the occurrence of GERD. Pharmaceutical agents that are used to prevent complications and reduce morbidity in patients with GERD include antacids, H2 receptor antagonists, proton pump inhibitors (PPIs), and prokinetic agents.
Technavios analysts forecast the global GERD drugs market to grow at a CAGR of 2.85% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global GERD drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of various drug classes used in the treatment of GERD.
The market is divided into the following segments based on geography:
Americas
APAC
Europe
Technavios report, Global GERD Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
AstraZeneca
Eisai
GlaxoSmithKline
Johnson & Johnson
Takeda
Other prominent vendors
Ahn-Gook Pharmaceutical
Cancer Advances
CJ Cheil Jedang
Daewoong Pharmaceutical
Ironwood Pharmaceuticals
RaQualia Pharma
SFJ Pharmaceuticals Group
Sucampo Pharmaceuticals
Vecta Pharmaceuticals
Wockhardt
Yuhan
Zeria Pharmaceutical
Market driver
Unmet medical needs
For a full, detailed list, view our report
Market challenge
Increased preference for CAM
For a full, detailed list, view our report
Market trend
Increase in awareness about GERD
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
Product profiles
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Types of GERD
Signs and symptoms
Risk factors
Diagnosis
Treatment
Usage of OTC drugs in GERD
Epidemiology
Economic burden
PART 06: Pipeline portfolio
Information on pipeline candidates
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by drug class
PART 09: Global antacids market
Introduction
Market overview
PART 10: Global PPI drugs market
Introduction
Market overview
PART 11: Global H2 receptor antagonist drugs market
Introduction
Market overview
PART 12: Market segmentation by route of administration38
Oral
Parenteral
PART 13: Market segmentation by dosage form
Solid
Liquid
PART 14: Geographical segmentation
Global GERD drugs market segmentation by geography
GERD drugs market in the Americas
GERD drugs market in EMEA
GERD drugs market in APAC
PART 15: Market drivers
Lifestyle factors
Overuse of medicines and dietary supplements
Unmet medical needs
Increase in prevalence of GERD
Cost-effective OTC drugs
PART 16: Impact of drivers
PART 17: Market challenges
Increased preference for CAM
Adverse effects of drugs
Generic erosion
Counterfeit drugs
PART 18: Impact of drivers and challenges
PART 19: Market trends
Self-medication
Increase in awareness about GERD
Intense competition
Strategic alliances
PART 20: Vendor landscape
Competitive scenario
PART 21: Key vendor analysis
AstraZeneca
Eisai
GSK
Johnson & Johnson
Takeda
Other prominent vendors
PART 22: Appendix
List of abbreviations
PART 23: Explore Technavio
List Of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Symptoms of pediatric GERD
Exhibit 03: GERD symptoms of older children and adolescents
Exhibit 04: Common risk factors for GERD
Exhibit 05: Dose, frequency, and average generic prices
Exhibit 06: Alternative treatment for GERD
Exhibit 07: Time line of the US FDA approved drugs for the treatment of GERD
Exhibit 08: Comparison between prescription and OTC drugs
Exhibit 09: Advantages and disadvantages of OTC drugs
Exhibit 10: Pipeline molecules for GERD
Exhibit 11: GERD clinical trials by development phase
Exhibit 12: GERD clinical trials by trial status
Exhibit 13: Global GERD drugs market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global GERD drugs market segmentation by drug class
Exhibit 16: Global GERD drugs market segmentation by drug class 2015
Exhibit 17: Global antacids market 2015-2020 ($ billions)
Exhibit 18: PPI sales in major non-US markets 2013 ($ millions)
Exhibit 19: Global PPIs market 2015-2020 ($ billions)
Exhibit 20: Global H2 receptor antagonists market 2015-2020 ($ billions)
Exhibit 21: Global GERD drugs market segmentation by route of administration
Exhibit 22: Global GERD drugs market segmentation by dosage form
Exhibit 23: Global GERD drugs market by geography 2015
Exhibit 24: Global GERD drugs market by geography 2015-2020 ($ billions)
Exhibit 25: GERD drugs market in the Americas 2015-2020 ($ billions)
Exhibit 26: GERD drugs market in EMEA 2015-2020 ($ billions)
Exhibit 27: GERD drugs market in APAC 2015-2020 ($ billions)
Exhibit 28: Impact of drivers
Exhibit 29: Common side effects associated with Nexium, Prontonix, Aciphex, and other heartburn medications
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 32: AstraZeneca: Business segmentation by revenue 2014
Exhibit 33: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 34: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 35: AstraZeneca: YoY revenue growth of Nexium 2012-2014 ($ billions)
Exhibit 36: AstraZeneca: YoY revenue growth of Losec 2012-2014 ($ millions)
Exhibit 37: AstraZeneca: YoY revenue growth of Vimovo 2012-2014 ($ millions)
Exhibit 38: AstraZeneca: Key takeaways
Exhibit 39: Eisai: Business segmentation by revenue 2014
Exhibit 40: Eisai: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 41: Eisai: YoY revenue growth of Pariet 2011-2014 ($ billions)
Exhibit 42: Eisai: Key takeaways
Exhibit 43: GSK: Business segmentation by revenue 2014
Exhibit 44: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: GSK: Geographical segmentation by revenue 2014
Exhibit 46: GSK: Key takeaways
Exhibit 47: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 48: Johnson & Johnson: Business segmentation 2013 and 2014 by revenue ($ billions)
Exhibit 49: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 50: Johnson & Johnson: Key takeaways
Exhibit 51: Takeda: Business segmentation by revenue 2014
Exhibit 52: Takeda: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 53: Takeda: Geographical segmentation by revenue 2014
Exhibit 54: Takeda: YoY revenue growth of Prevacid 2012-2014 ($ billions)
Exhibit 55: Takeda: YoY revenue growth of Dexilant 2012-2014 ($ billions)
Exhibit 56: Takeda: YoY revenue growth of Protonix 2012-2014 ($ billions)
Exhibit 57: Takeda: Key takeaways
